The New England journal of medicine
-
Editorial Comment
Molnupiravir - A Step toward Orally Bioavailable Therapies for Covid-19.
-
Randomized Controlled Trial
Survival with Cemiplimab in Recurrent Cervical Cancer.
Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, the fully human programmed cell death 1 (PD-1)-blocking antibody approved to treat lung and skin cancers, has been shown to have preliminary clinical activity in this population. ⋯ Survival was significantly longer with cemiplimab than with single-agent chemotherapy among patients with recurrent cervical cancer after first-line platinum-containing chemotherapy. (Funded by Regeneron Pharmaceuticals and Sanofi; EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 ClinicalTrials.gov number, NCT03257267.).